Close Menu

More articles about Tissue-Based Testing

With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.

The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.

The digital pathology system can be used for primary diagnosis as a result of the 510(k) clearance, which followed a multicenter study conducted at five clinical sites.

The approach makes use of a microfluidic probe that allows researchers to more effectively collect data on the kinetics of antibody-target reactions.

The Boston-based company said it will use the funding in part to  continue refining its artificial intelligence-powered pathology research platform.

The firm said that it will use the funding to support business activities to meet demand for its approach to clinical trial recruitment.

The companies anticipate providing services that combine Flagship’s biomarker development and Indivumed’s multiplex IHC assay development capabilities.

The device, called the MasSpec Pen, was developed by University of Texas researchers to help more quickly and accurately assess margins during cancer surgery.

The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.

According to the researchers, the method could enable higher-throughput analyses while removing some of the subjectivity inherent in pathology practice.

The firms launched OptraScan's Global TelePath Network in the UAE, India, and South Africa under the partnership, named Neuberg Digipath, Powered by OptraScan.

The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.

A US expansion was logical because "there is high recognition [here] of the value that diagnostics can bring to the patient and to the oncologist," its CEO said.

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

The business is part of Thermo Fisher's Specialty Diagnostics segment and generates about $350 million in revenues annually.

The solutions being developed will leverage AI from labs globally and will accelerate the number of new test algorithms available to the lab diagnostics market.

The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.

PGDx and KingMed plan to provide tumor mutational burden testing to pharmaceutical companies for clinical trials in China and Hong Kong.

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

The French firm reached five new deals covering 15 countries for its Immunoscore test, which helps physicians assess colon cancer prognosis.

Pages